Examiner

PTO/SB/08a (01-09)
Approved for use through 02/28/2009. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use infloring 1/2/28/2019. ONB 0/651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

				Complete if Known	
Substitute for form 1449A/PTO				Application Number	10/511,980
INFORMATION DISCLOSURE				Filing Date	4/7/2005
				First Named Inventor	Amalfitano et al.
STATEMENT BY APPLICANT				Art Unit	1633
(Use as many sheets as necessary)				Examiner Name	Fereydoun Ghotb Sajjadi
Sheet	1	of	2	Attorney Docket Number	180/151 PCT/US

			U.S. PATENT		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2 (Vitrosen)</sup>		Applicant of Cited Document	
/F.G.S.	/ 1	US-6,329,958	12-11-2001	McLean et al.	
-	2	US-6,329,181	12-11-2001	Xiao et al.	
	3	US-6,294,370	09-25-2001	Bogedain et al.	
	4	US-6,270,996	08-07-2001	Wilson et al.	
	5	US-6,258,595	07-10-2001	Gao et al.	
	6	US-5,872,005	02-16-1999	Wang et al.	
V	7	US-5,871,982	02-16-1999	Wilson et al.	
		US-			
		US-			
		US-			*************************
		US-			
		US-			***************************************
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>0</sup>
						⊢
						H

Signature	/r crcyddan ddjiadii	Conside	red 0772372003
*EXAMINER: II	nitial if reference considered, whether or not citation is in confor	mance with MPEP 609. Draw	line through citation if not in conformance and not
considered. In	clude copy of this form with next communication to applicant. 1	Applicant's unique citation des	ignation number (optional). 2See Kinds Codes of

/Earaudoup Calladi/

Date

07/00/0000

considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional), "See Kinds Codes of USPTO Patent Documents at <a href="https://www.ussio.googvo.org">www.ussio.googvo.org</a> (MPEP 901.04. "Enter Office that issued the document, by the two-letter code (NIPPO Standard ST.3), "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached."

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFFO by process) an application. Confidentially is powered by 58 U.S. C. 22 and 37 CFR 1.14 This collection is estimate to take 2 neuron to complete, including gathering, preparing, and submitting the completed application from to the USFFO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestance for reducing this burden, should be sent to the Other Information (USFFO). The value of the Comment of the power of the Comment of the power of the Comment of the power of the Comment of the

Receipt date: 07/13/2009

Examiner

/Fereydoun Sajjadi/

PTO/SB/08b (01-09)

Approved for use through 02/28/2009. OMB 0551-031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF U.S. Patent and Trademark Office; U.S. DEPARTMENT OF U.S. Patent and Trademark Office; U.S. DEPARTMENT OF U.S. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF U.S. Patent and U.S. Patent and U.S. Patent D.S. Patent And U.S. Patent D.S. Patent Complete if Known Substitute for form 1449B/PTO Application Number 10/511.980 Filing Date 4/7/2005 INFORMATION DISCLOSURE First Named Inventor Amalfitano et al. STATEMENT BY APPLICANT Art Unit 1633 Examiner Name Fereydoun Ghotb Sajjadi (Use as many sheets as necessary) Sheet 2 Attorney Docket Number 180/151 PCT/US of

Examiner   Cite   Include name of the author (in CAPITAL LETTES); tite of the article (when appropriate), title of the item (book, midfals)   midgazine, journal, sorial, symposium, acatash, obt. date, page 14.   F. G.S.   8   Allen et al., "Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E-dor," Mol. Ther., Vol. 1, pgs. 88-95 (2000).   9   Armafitano et al., "Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted," J. Virol, Vol. 72, pgs. 926-933 (1989).   10   Armafitano et al., "Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted," J. Virol, Vol. 72, pgs. 926-933 (1989).   11   Armafitano et al., "Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-a-glucosidase," PNAS, Vol. 96, pgs. 8861-8866 (1999).   12   Gao et al., "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap," Mol. Ther., Vol. 5, pgs. 253-2382 (1998).   13   He et al., "A simplified system for generating recombinant adenoviruses," PNAS, Vol. 95, pgs. 2509-2514 (1998).   14   Hodges et al., "Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein," J. Gene Med., Vol. 2, pgs. 250-258 (2000).   15   Liber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Medilated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo," J. Virol., Vol. 70, pgs. 8944-8980 (1996).   16   Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a Nyorior recombinant adenovirus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).   18   Sun et al., "Prackaging of an AAV Vector Fooding Human Acid α-Glucosidase for Gen			NON PATENT LITERATURE DOCUMENTS	
F.G.S./ 8	Examiner Initials*	Cite No.	Allen et al., "Improved Adeno-Associated Virus Vector Production with Transfection of a Single	
Ebb, and E3 Genes Deleted," J. Virol., Vol. 72, pgs. 926-933 (1998).  Amalitane et al., "Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-a-glucosidase," PNAS, Vol. 96, pgs. 8861-8866 (1999).  Gao et al., "High-Tier Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus," Hum. Gene Ther., Vol. 9, pgs. 2353-2362 (1998).  Zao et al., "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap," Mol. Ther., Vol. 5, pgs. 644-649 (2002).  He et al., "As implified system for generating recombinant adenoviruses," PNAS, Vol. 95, pgs. 2509-2514 (1998).  Hodges et al., "Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein," J. Gene Med., Vol. 2, pgs. 250-259 (2000).  Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Ceneration Vectors in Vitro and In Vivo," J. Virol., Vol. 70, pgs. 8944-9860 (1996).  Lie et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).  Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun tel., "Packaging of an AAV Vector Encoding Human Acid o-Clucosidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Howe et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and cornects glycogen accumulation in fibroblasts from patients with Prompe diseases," PNAS, Vol. 93, pgs. 65-70 (1966).	/F.G.S./	8		
10 hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase," PNAS, Vol. 96, pgs. 886-1886 (1999).  11 Gao et al., "High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus," Hum. Gene Ther., Vol. 9, pgs. 2353-2362 (1998).  12 Gao et al., "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap," Mol. Ther., Vol. 5, pgs. 644-649 (2002).  13 He et al., "As simplified system for generating recombinant adenoviruses," PNAS, Vol. 95, pgs. 2509-2514 (1998).  14 Hodges et al., "Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein," J. Gene Med., Vol. 2, pgs. 250-259 (2000).  15 Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Ceneration Vectors in Vitro and in Vivo," J. Virol., Vol. 70, pgs. 8944-6980 (1996).  16 Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).  17 Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AAV Vector Encoding Human Acid o-Glucosidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-Hevel production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and cornects glycogen accumulation in fibroblasts from patients with Pompe diseases," PNAS, Vol. 93, pgs. 657-01 (1996).		9	Amalfitano et al., "Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted," J. Virol., Vol. 72, pgs. 926-933 (1998).	
1		10	hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase," PNAS, Vol. 96, pgs. 8861-8866 (1999).	
12		11	Virus," Hum. Gene Ther., Vol. 9, pgs. 2353-2362 (1998).	
14 Hodges et al., "Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein," J. Gene Med., Vol. 2, pgs. 250-259 (2000).  Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Ceneration Vectors in Vitro and in Vivo," J. Virol., Vol. 70, pgs. 894-48980 (1996).  Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gener Ther., Vol. 6, pgs. 293-299 (1999).  Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AAV Vector Encoding Human Acid -Giucosidase for Gene Therapy in Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe diseases," PNAS, Vol. 93, pgs. 65-70 (1996).		12		
deletion of the preterminal protein, "J. Gene Med., Vol. 2, pgs. 250-259 (2000).   Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors in Vitro and in Vivo," J. Virol, Vol. 70, pgs. 8944-9890 (1996).  16 Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).  17 Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AAV Vector Encoding Human Acid o-Glucosidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe diseases," PNAS, Vol. 39, pgs. 657-07 (1996).		13		
15 Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo," J. Virol., Vol. 70, gps. 8944-8980 (1996).  16 Liu et al., "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).  17 Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AV Vector Encoding Human Acid «-Gluccaidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe diseases," PNAS, Vol. 39, pgs. 65-70 (1996).		14		
a hybrid recombinant adenovirus," Gene Ther., Vol. 6, pgs. 293-299 (1999).  Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," Current Topics in Microsloology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AAV Vector Encoding Human Acid α-Glucosidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," PNAS, Vol. 93, pgs. 65-70 (1996).		15	Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo,"	
1 cells," Current Topics in Microbiology and Immunology, Vol. 158, pgs. 97-129 (1992).  Sun et al., "Packaging of an AAV Vector Encoding Human Acid o-Glucosidase for Gene Therapy In Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Howe et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe diseases," PNAS, Vol. 39, pgs. 65-70 (1969).		16		
Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol. 7, pgs. 467-477 (2003).  Van Hove et al., "High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," PNAS, Vol. 93, pgs. 65-70 (1965).		17		
19 Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," PNAS, Vol. 93, pgs. 65-70 (1996).		18	Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector," Mol. Ther., Vol.	
		19	Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," PNAS, Vol. 93, pgs. 65-70 (1996).	
<sup>2U</sup> replication centers," J. Virol., Vol. 70, No. 3, pgs. 1845-1854 (1996).		20		
Zhang et al., "Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus," Gene Ther., Vol. 8, pgs. 704-712 (2001).	$\bigvee$	21	supports production of high-titer recombinant adeno-associated virus," Gene Ther., Vol. 8, pgs. 704-	

Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Date

07/29/2009

considered. Include copy of this form with next communication to applicant.

Applicants unique citation designation numble (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1,9 in the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.